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Although durable responses to single agent immune
checkpoint inhibitors have been reported, additional
approaches are needed to extend this therapeutic benefit
to a greater proportion of cancer patients. Accordingly,
substantial efforts are ongoing to identify agents that can
augment T cell-mediated killing of tumor cells and
potentiate the effects of checkpoint inhibitors. Focal Adhe-
sion Kinase (FAK) and the closely related family member
PYK2 are potentially valuable targets in this regard due to
the roles of these protein kinases in regulating key cellular
populations in the tumor microenvironment. In addition
to the potency of the small molecule FAK/PYK2 inhibitors
defactinib (VS-6063) and VS-4718 to target cancer stem
cells, we have also reported that these agents inhibited
monocyte-derived macrophages, decreased IL-6 produc-
tion from macrophages in vitro, and reduced tumor-asso-
ciated macrophages in xenograft models.
We now report that defactinib and VS-4718 stimulate
proliferation of CD8+ cytotoxic T cells. This is in distinct
contrast to other protein kinase inhibitors, such as the
SRC inhibitor dasatinib and the MEK inhibitor trameti-
nib, which potently impair the proliferation of CD8+
cytotoxic T cells. Using primary human CD8+ T cells
isolated from healthy donors, both FAK/PYK2 inhibitors
dose-dependently increased proliferation of CD8+ T cells
in the presence of anti-CD3/anti-CD28 coated beads.
Based on the observed enhancement of CD8+ T cells
and previously noted inhibition of tumor-associated
macrophages, we investigated whether FAK/PYK2 inhi-
bitors potentiate the anti-tumor efficacy of an anti-PD-1
monoclonal antibody in syngeneic mouse tumor models.
Mice bearing established MC38 colorectal tumors were
treated with VS-4718 in combination with an anti-PD-1
antibody. Combination of VS-4718 with anti-PD-1
extended the median overall survival to 42 days relative
to 21, 25 and 28 day median overall survival with vehi-
cle control, single agent anti-PD-1 and single agent VS-
4718, respectively. Moreover, on day 56, 30% of mice
treated with the VS-4718/anti-PD-1 combination were
alive in contrast to the vehicle control, single agent VS-
4718, and single agent anti-PD-1 groups in which no
mice survived. Studies are currently underway to better
understand the immune cell changes in these tumors
following VS-4718 and anti-PD-1 combination therapy.
These data provide a rationale for clinical trials in
cancer patients to test whether a FAK/PYK2 inhibitor in
combination with an immune checkpoint inhibitor
could increase the breadth of responsive tumor types,
increase the number of responders, and confer a more
durable anti-tumor response.
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